Least-squares means (95% confidence intervals) of daily nutrient intake of study participants in men according to frailty groups. by Subeen Kim (11714313)

Mean values (± standard deviation) of hormonal parameters before and after CWI. by Aneta Teległów (9570190)

Mean values (± standard deviation) of electrolyte concentrations before and after CWI. by Aneta Teległów (9570190)

Mean values (± standard deviation) of liver profile parameters before and after CWI. by Aneta Teległów (9570190)

Mean values (± standard deviation) of renal profile parameters before and after CWI. by Aneta Teległów (9570190)

Mean values (± standard deviation) of lipid profile parameters before and after CWI. by Aneta Teległów (9570190)

Mean values (± standard deviation) of CK, CK-MB and LDH before and after CWI. by Aneta Teległów (9570190)

Random forest plot showing the importance of predictors (top 10) for classifying LF progression based on the Mean Decrease in Gini index. by Emmanuel Kobla Atsu Amewu (13946765)

The means pre-death food intake of all participants and each 4 groups for 24 weeks to death (Range 1-10). by Sakiko Fukui (387048)

Subjects:

Average mean decrease Gini across 100 partitions for the top 10 most important variables for binary mixed model and random forest. by Helal El-Zaatari (20442243)

“…<p>Average mean decrease Gini across 100 partitions for the top 10 most important variables for binary mixed model and random forest.…”

Mean scores of IB-DE, IH-DE, and IB-DE items in Sample 1 and Sample 2 as well as women and men across the samples. by Aistė Ambrasė (22505574)

Univariable and multivariable analyses (age-adjusted), concerning a selection of medicaments p < 0.1 and n ≥ 10. by P.G.J. ter Horst (21743830)

Subjects:

Least-squares means (95% confidence intervals) of daily nutritional intake of study participants in women according to Frailty Groups. by Subeen Kim (11714313)

Comparison of the albendazole and ivermectin parasitological cure rate (Intention-to-treat). by Luccheri Ndong Akomezoghe (18585684)

Subjects:

Evolution of the frequency of <i>Loa loa</i> clinical symptoms over the 30-day follow-up period. by Luccheri Ndong Akomezoghe (18585684)

Subjects:

Eosinophil rate progression by treatment. by Luccheri Ndong Akomezoghe (18585684)

Subjects:

Descriptive characteristics of the two treatment groups at the inclusion (D0). by Luccheri Ndong Akomezoghe (18585684)

Subjects:

Evolution of clinical adverse events over the 30-day follow-up period. by Luccheri Ndong Akomezoghe (18585684)

Subjects:

Comparison of the albendazole and ivermectin parasitological cure rate (Per-protocol). by Luccheri Ndong Akomezoghe (18585684)

Subjects:

Study flowchart. by Luccheri Ndong Akomezoghe (18585684)

Subjects: